You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events

Article info

Article menu

Download PDFPDF

XML
Short Report
Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events

Authors

  • Yousef R. Badran Department of MedicineMassachusetts General Hospital 02114 Boston MA USA Harvard Medical School 02115 Boston MA USA PubMed articlesGoogle scholar articles
  • Justine V. Cohen Harvard Medical School 02115 Boston MA USA Division of Oncology, Department of MedicineMassachusetts General Hospital 02114 Boston MA USA PubMed articlesGoogle scholar articles
  • Priscilla K. Brastianos Harvard Medical School 02115 Boston MA USA Division of Oncology, Department of MedicineMassachusetts General Hospital 02114 Boston MA USA PubMed articlesGoogle scholar articles
  • Aparna R. Parikh Harvard Medical School 02115 Boston MA USA Division of Oncology, Department of MedicineMassachusetts General Hospital 02114 Boston MA USA PubMed articlesGoogle scholar articles
  • Theodore S. Hong Harvard Medical School 02115 Boston MA USA Department of Radiation Oncology, Department of MedicineMassachusetts General Hospital 02114 Boston MA USA PubMed articlesGoogle scholar articles
  • Michael Dougan Harvard Medical School 02115 Boston MA USA Division of Gastroenterology, Department of MedicineMassachusetts General Hospital 02114 Boston MA USA PubMed articlesGoogle scholar articles
  1. ↵f mldougan{at}partners.org
View Full Text

Citation

Badran YR, Cohen JV, Brastianos PK, et al
Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events
Journal for ImmunoTherapy of Cancer 2019;7:226. doi: 10.1186/s40425-019-0711-0

Publication history

  • Received June 27, 2019
  • Accepted August 14, 2019
  • First published August 22, 2019.
Online issue publication 
January 08, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.